Puration Inc Publishes Telluride Health Company Acquisition Shareholder Presentation
DALLAS, TX – November 5, 2018 - Puration, Inc. (USOTC: PURA) (“PURA”) today released an online presentation with details on the recent acquisition of the Telluride Health Company and the plans for integrating the operation into PURA’s overall cannabis beverage business model. The presentation includes an explanation of how PURA fits into the ACI Conglomerated portfolio in conjunction with ACI’s other holdings, North American Cannabis Holdings (USMJ), Priority Aviation (PJET) and Nouveau Life Pharmaceuticals (NOUV). The presentation is available on the company’s website. The narrative from the presentation is included in its entirety below.
PURA’s Telluride Health Company Acquisition and The ACI Family
The Telluride Health Company is the brain child of a group of college students that are active cannabis community participants. They developed Telluride Happy Water to enhance the cannabis experience by consuming Telluride Happy Water before partaking or otherwise using Telluride Happy Water in their water pipe. The group produced a pilot quantity of Telluride Happy Water and tested within their own network and by knocking on the doors of retail cannabis shops and setting up trials with the cannabis shops clients. They decided to position Telluride Health Company in a public holding company in order to get access to financing to take Telluride Happy Water into production. That’s how Telluride Health Company came to Priority Aviation, Inc. (USOTC: PJET) (“PJET”). The public company learning curve has been steep for the group and getting into production has taken longer than anticipated.
“I’m very happy to have Telluride Health Company become part of the Puration family,” said Yasmine Acebo, president of Telluride Health Company. “Leveraging Puration’s experience in the public company arena and in producing beverages frees us up to focus on sales and marketing of Telluride Happy Water.”
“The Telluride Health Company team has a wonderful product in an absolutely unique space,” said Brian Shibley, CEO of Puration. “We have not found another designer water-pipe water on the market. Telluride Happy Water, as far as our research indicates, has no competitors and plenty of demand. We’ve already started production of Telluride Happy Water and expect to have it on shelves before the end of the year.”
Telluride Happy Water has a higher level of dissolved oxygen in it than almost any bottled water on the market. A patented technology and formula reduces the size of water molecules which creates a platform that accelerates the uptake of anything mixed with or filtered through the patented water technology. This is how our product exponentially increases a cannabis high.
The cannabis-infused edibles market is projected to make up a $2.3-billion market in 2018 and to become a $5.3-billion market within the next five years, according to data from cannabis market research firm Brightfield Group.
The majority shareholder of Puration, Inc. is a private company called ACI Conglomerated (“ACI”). ACI also owns the majority interest of North American Cannabis Holdings, Inc. (USMJ). ACI now also owns the majority interest of PJET and anticipates soon owning control of Nouveau Life Pharmaceuticals (NOUV). PJET is now being repurposed in conjunction with owning and operating the AmeriCanna Cafe, acquired from USMJ. NOUV is being repurposed in conjunction with owning the cannabis cultivation operations it acquired from PURA. ACI’s mission is to invest in and grow a portfolio of cannabis enterprises.
USMJ PURA PJET NOUV
Cannabis Cannabis Cannabis Themed Cannabis
E-commerce Beverages Restaurants Cultivation
The ACI management team strategy is to efficiently operate the portfolio of cannabis enterprises in a manner that enhances the shareholder value of each company in the portfolio. The portfolio company business models all over lap leveraging resources and market segments one from the other. The ACI approach is unique in the cannabis sector and sets the portfolio companies appart from their competition.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.